Management of CADASIL syndrome

Bibliography

• Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-10
   PubMed Web of Science ®Google Scholar
• Chabriat H, Joutel A, Dichgans M, et al. CADASIL. Lancet Neurol 2009;8:643-53
   PubMed Web of Science ®Google Scholar
• Ruchoux MM, Guerouaou D, Vandenhaute B, et al. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol 1995;89:500-12
   PubMed Web of Science ®Google Scholar
• Razvi SS, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry 2005;76:739-41
   PubMed Web of Science ®Google Scholar
• Stromillo ML, Dotti MT, Battaglini M, et al. Structural and metabolic brain abnormalities in preclinical cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy. J Neurol Neurosurg Psychiatry 2009;80:41-7
   PubMed Web of Science ®Google Scholar
• Rinnoci V, Nannucci S, Valenti R, et al. Cerebral haemorrhages in CADASIL: report of four cases and a brief review. J Neurol Sci 2013;330:45-51
   PubMed Web of Science ®Google Scholar
• Chabriat H, Vahedi K, Iba-Zizen MT, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995;346:934-9
   PubMed Web of Science ®Google Scholar
• Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 1998;44:731-9
   PubMed Web of Science ®Google Scholar
• Peters N, Herzog J, Opherk C, Dichgans M. A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke 2004;35:1603-8
   PubMed Web of Science ®Google Scholar
• Trojano L, Ragno M, Manca A, Caruso G. A kindred affected by cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). A 2-year neuropsychological follow-up. J Neurol 1998;245:217-22
   PubMed Web of Science ®Google Scholar
• Amberla K, Waljas M, Tuominen S, et al. Insidious cognitive decline in CADASIL. Stroke 2004;35:1598-602
   PubMed Web of Science ®Google Scholar
• Buffon F, Porcher R, Hernandez K, et al. Cognitive profile in CADASIL. J Neurol Neurosurg Psychiatry 2006;77:175-80
   PubMed Web of Science ®Google Scholar
• Peters N, Opherk C, Danek A, et al. The pattern of cognitive performance in CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia. Am J Psychiatry 2005;162:2078-85
   PubMed Web of Science ®Google Scholar
• Román GC, Erkinjuntti T, Wallin A, et al. Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1:426-36
   PubMed Web of Science ®Google Scholar
• Chabriat H, Tournier-Lasserve E, Vahedi K, et al. Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. Neurology 1995;45:1086-91
   PubMed Web of Science ®Google Scholar
• Gunda B, Hervè D, Godin O, et al. Effects of gender on the phenotype of CADASIL. Stroke 2012;43:137-41
   PubMed Web of Science ®Google Scholar
• Singhal S, Rich P, Markus HS. The spatial distribution of MR imaging abnormalities in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and their relationship to age and clinical features. AJNR Am J Neuroradiol 2005;26:2481-7
   PubMed Web of Science ®Google Scholar
• Valenti R, Poggesi A, Pescini F, et al. Psychiatric disturbances in CADASIL: a brief review. Acta Neurol Scand 2008;118:291-5
   PubMed Web of Science ®Google Scholar
• Ragno M, Pianese L, Cacchiò G, et al. Multi-organ investigation in 16 CADASIL families from central Italy sharing the same R1006C mutation. Neurosci Lett 2012;506:116-20
   PubMed Web of Science ®Google Scholar
• Reyes S, Viswanathan A, Godin O, et al. Apathy: a major symptom in CADASIL. Neurology 2009;72:905-10
   PubMed Web of Science ®Google Scholar
• Ragno M, Berbellini A, Cacchiò G, et al. Parkinsonism is a late, not rare, feature of CADASIL. A study on Italian patients carrying the R1006C mutation. Stroke 2013;44:1147-9
   PubMed Web of Science ®Google Scholar
• Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke 2010;41:630-4
   PubMed Web of Science ®Google Scholar
• Ragno M, Pianese L, Morroni M, et al. “CADASIL coma” in an Italian homozygous CADASIL patient: comparison with clinical and MRI findings in age-matched heterozygous patients with the same G528C NOTCH3 mutation. Neurol Sci 2013; Epub ahead of print
   Web of Science ®Google Scholar
• de la Peña P, Bornstein B, del Hoyo P, et al. Mitochondrial dysfunction associated with a mutation in the Notch3 gene in a CADASIL family. Neurology 2001;57:1235-8
   PubMed Web of Science ®Google Scholar
• Finnilä S, Tuisku S, Herva R, Majamaa K. A novel mitochondrial DNA mutation and a mutation in the Notch3 gene in a patient with myopathy and CADASIL. J Mol Med 2001;79:641-7
   PubMed Web of Science ®Google Scholar
• Malandrini A, Albani F, Palmeri S, et al. Asymptomatic cores and paracrystalline mitochondrial inclusions in CADASIL. Neurology 2002;59:617-20
   PubMed Web of Science ®Google Scholar
• Ragno M, Trojano L, Pianese L, et al. Renal involvement in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): report of a case with a six-year follow-up. Histol Histopathol 2012;27:1307-14
   PubMed Web of Science ®Google Scholar
• Lesnik Oberstein SA, Jukema JW, Van Duinen SG, et al. Myocardial infarction in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Medicine (Baltimore) 2003;82:251-6
   PubMed Web of Science ®Google Scholar
• Zicari E, Tassi R, Stromillo ML, et al. Right-to-left shunt in CADASIL patients: prevalence and correlation with clinical and MRI findings. Stroke 2008;39:2155-7
   PubMed Web of Science ®Google Scholar
• Pretegiani E, Rosini F, Dotti MT, et al. Visual system involvement in CADASIL. J Stroke Cerebrovasc Dis 2013; S1052-3057(13)00114-6
   Web of Science ®Google Scholar
• Kang SY, Oh JH, Kang JH, et al. Nerve conduction studies in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neurol 2009;256:1724-7
   PubMed Web of Science ®Google Scholar
• Opherk C, Peters N, Herzog J, et al. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain 2004;127:2533-9
   PubMed Web of Science ®Google Scholar
• Appelrose P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke 2009;40:1082-90
   PubMed Web of Science ®Google Scholar
• Mykkänen K, Junna M, Amberla K, et al. Different clinical phenotypes in monozygotic CADASIL twins with a novel NOTCH3 mutation. Stroke 2009;40:2215-18
   PubMed Web of Science ®Google Scholar
• Singhal S, Bevan S, Barrick T, et al. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 2004;127:2031-8
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-5
   PubMed Web of Science ®Google Scholar
• Peters N, Freilinger T, Opherk C, et al. Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. J Neurol Sci 2007;260:100-5
   PubMed Web of Science ®Google Scholar
• Holtmannspötter M, Peters N, Opherk C, et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a 2-year follow-up study. Stroke 2005;36:2559-65
   PubMed Web of Science ®Google Scholar
• Peters N, Holtmannspötter M, Opherk C, et al. Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease. Neurology 2006;66:1517-22
   PubMed Web of Science ®Google Scholar
• Sharp SI, Aarsland D, Day S, et al. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 2011;26:661-9
   PubMed Web of Science ®Google Scholar
• Chabriat H, Bousser MG, Pappata S. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: a positron emission tomography study in two affected family members. Stroke 1995;26:1729-30
   PubMed Web of Science ®Google Scholar
• Tuominen S, Miao Q, Kurki T, et al. Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke 2004;35:1063-7
   PubMed Web of Science ®Google Scholar
• Chabriat H, Bousser MG. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Handb Clin Neurol 2008;89:671-86
   PubMedGoogle Scholar
• Sacco S, Rasura M, Cao M, et al. CADASIL presenting as status migrainosus and persisting aura without infarction. J Headache Pain 2009;10:51-3
   PubMed Web of Science ®Google Scholar
• Weller M, Dichgans J, Klockgether T. Acetazolamide-responsive migraine in CADASIL. Neurology 1998;50:1505
   PubMed Web of Science ®Google Scholar
• Forteza AM, Brozman B, Rabinstein AA, et al. Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology 2001;57:2144-5
   PubMed Web of Science ®Google Scholar
• Donnini I, Nannucci S, Valenti R, et al. Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience. J Headache Pain 2012;13:299-302
   PubMed Web of Science ®Google Scholar
• Settakis G, Molnàr C, Kerènyi L, et al. Acetazolamide as a vasodilatatory stimulus in cerebrovascular diseases and in conditions affecting the cerebral vasculature. Eur J Neurol 2003;10:609-20
   PubMed Web of Science ®Google Scholar
• Huang L, Yang Q, Zhang L, et al. Acetazolamide improves cerebral hemodynamics in CADASIL. J Neurol Sci 2010;292:77-80
   PubMed Web of Science ®Google Scholar
• Chabriat H, Pappata S, Ostergaard L, et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke 2000;31:1904-12
   PubMed Web of Science ®Google Scholar
• Park SA, Yang CY, Choi SS, Kim WH. Assessment of cerebral hemodynamics to acetazolamide using brain perfusion SPECT in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Clin Nucl Med 2011;36:158-9
   PubMed Web of Science ®Google Scholar
• Sacco S, Degan D, Carolei A. Diagnostic criteria for CADASIL in the international classification of headache disorders (ICHD-II): are they appropriate? J Headache Pain 2010;11:180-6
   Web of Science ®Google Scholar
• Skyhøj Olsen T. Migraine with and without aura: the same disease due to cerebral vasospasm of different intensity. A hypothesis based on CBF studies during migraine. Headache 1990;30:269-72
   PubMed Web of Science ®Google Scholar
• Robbins MS, Lipton RB, Laureta EC, Grosberg BM. CACNA1A nonsense mutation is associated with basilar-type migraine and episodic ataxia type 2. Headache 2009;49:1042-6
   PubMed Web of Science ®Google Scholar
• Tricarico D, Barbieri MG, Conte Camerino D. Acetazolamide opens the muscular KCa2 channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Ann Neurol 2000;48:304-12
   PubMed Web of Science ®Google Scholar
• Omata T, Takanashi J, Wada T, et al. Genetic diagnosis and acetazolamide treatment of familial hemiplegic migraine. Brain Dev 2011;33:332-4
   PubMed Web of Science ®Google Scholar
• De Simone R, Marano E, Di Stasio E, et al. Acetazolamide efficacy and tolerability in migraine with aura: a pilot study. Headache 2005;45:385-6
   PubMed Web of Science ®Google Scholar
• Van Guldener C, Stehouwer CD. Homocysteine-lowering treatment: an overview. Expert Opin Pharmacother 2001;2:1449-60
   PubMedGoogle Scholar
• Sathe S, DePeralta E, Pastores G, Kolodny EH. Acute confusional migraine may be a presenting feature of CADASIL. Headache 2009;49:590-6
   PubMed Web of Science ®Google Scholar
• Ducros A, Denier C, Joutel A, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med 2001;345:57-9
   PubMed Web of Science ®Google Scholar
• Eikermann-Haerter K, Yuzawa I, Dilekoz E, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome mutations increase susceptibility to spreading depression. Ann Neurol 2011;69:413-18
   PubMed Web of Science ®Google Scholar
• Martikainen MH, Roine S. Rapid improvement of a complex migrainous episode with sodium valproate in a patient with CADASIL. J Headache Pain 2012;13:95-7
   PubMed Web of Science ®Google Scholar
• Videbech P. MRI findings in patients with affective disorder: a meta-analysis. Acta Psychiatr Scand 1997;96:157-68
   PubMed Web of Science ®Google Scholar
• Taylor WD, Steffens DC, Macfall JR, et al. White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry 2003;60:1090-6
   PubMed Web of Science ®Google Scholar
• Macritchie K, Geddes JR, Scott J, et al. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003;CD004052
   PubMedGoogle Scholar
• Gidal BE, Pitterle ME, Spencer NW, Maly MM. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. J Clin Pharm Ther 1995;20:215-19
   PubMed Web of Science ®Google Scholar
• Yuan P, Salvadore G, Li X, et al. Valproate activates the Notch3/c-FLIP signalling cascade: a strategy to attenuate white matter hyperintensities in bipolar disorder in late life? Bipolar Disord 2009;11:256-69
   PubMed Web of Science ®Google Scholar
• Beghi E, D'Alessandro R, Beretta S, et al. Epistroke Group. Incidence and predictors of acute symptomatic seizures after stroke. Neurology 2011;77:1776-8
   PubMed Web of Science ®Google Scholar
• Giroud M, Gras P, Fayolle H, et al. Early seizures after acute stroke: a study of 1640 cases. Epilepsia 1994;35:959-64
   PubMed Web of Science ®Google Scholar
• De Reuck J, Nagy E, Van Maele G. Seizures and epilepsy in patients with lacunar strokes. J Neurol Sci 2007;263:75-8
   PubMed Web of Science ®Google Scholar
• Okroglic S, Widmann CN, Horst Urbach H, et al. Clinical symptoms and risk factors in cerebral microangiopathy patients. PLoS ONE 2013;8:e53455
   PubMed Web of Science ®Google Scholar
• Olsen TS, Langhorne P, Diener HC, et al. European Stroke Initiative executive Committee and the EUSI Writing Committee. European stroke initiative recommendations for stroke management – update 2003. Cerebrovasc Dis 2003;16:311-37
   PubMed Web of Science ®Google Scholar
• Gilad R, Sadeh M, Rapoport A, et al. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clin Neuropharmacol 2007;30:189-95
   PubMed Web of Science ®Google Scholar
• Alvarez-Sabin J, Montaner J, Padro I, et al. Gabapentin in late onset poststroke seizures. Neurology 2002;59:1991-3
   PubMed Web of Science ®Google Scholar
• Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 2003;20:141-52
   PubMed Web of Science ®Google Scholar
• Kutlu G, Gomceli YB, Unal Y, Inan LE. Leviracetam monotherapy for late poststroke seizures in the elderly. Epilepsy Behav 2008;13:542-4
   PubMed Web of Science ®Google Scholar
• Consoli D, Bosco D, Postorino P, et al. Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Cerebrovasc Dis 2012;34:282-28
   PubMed Web of Science ®Google Scholar
• Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-52
   PubMed Web of Science ®Google Scholar
• Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-76
   PubMed Web of Science ®Google Scholar
• European Stroke Organisation (ESO) Executive Committee and ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis 2008;25:457-507
   PubMed Web of Science ®Google Scholar
• Benavente OR, Hart RG, McClure LA, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817-25
   PubMed Web of Science ®Google Scholar
• Molko N, Pappata S, Mangin JF, et al. Monitoring disease progression in CADASIL with diffusion magnetic resonance imaging: a study with whole brain histogram analysis. Stroke 2002;33:2902-8
   PubMed Web of Science ®Google Scholar
• Benisty S, Hernandez K, Viswanathan A, et al. Diagnostic criteria of vascular dementia in CADASIL. Stroke 2008;39:838-44
   PubMed Web of Science ®Google Scholar
• Stern Y. Cognitive reserve. Neuropsychologia 2009;47:2015-28
   PubMed Web of Science ®Google Scholar
• Zieren N, Duering M, Peters N, et al. Education modifies the relation of vascular pathology to cognitive function: cognitive reserve in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurobiol Aging 2013;34:400-7
   PubMed Web of Science ®Google Scholar
• Viswanathan A, Gschwendtner A, Guichard JP, et al. Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL. Neurology 2009;69:172-9
   Web of Science ®Google Scholar
• O'Sullivan M, Ngo E, Viswanathan A, et al. Hippocampal volume is an independent predictor of cognitive performance in CADASIL. Neurobiol Aging 2009;30:890-7
   PubMed Web of Science ®Google Scholar
• Keverne JS, Low WC, Ziabreva I, et al. Cholinergic neuronal deficits in CADASIL. Stroke 2007;38:188-91
   PubMed Web of Science ®Google Scholar
• Manganelli F, Ragno M, Cacchiò G, et al. Motor cortex cholinergic dysfunction in CADASIL: a transcranial magnetic demonstration. Clin Neurophysiol 2008;119:351-5
   PubMed Web of Science ®Google Scholar
• Palomar FJ, Suárez A, Franco E, et al. Abnormal sensorimotor plasticity in CADASIL correlates with neuropsychological impairment. J Neurol Neurosurg Psychiatry 2013;84:329-36
   PubMed Web of Science ®Google Scholar
• Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008;7:310-18
   PubMed Web of Science ®Google Scholar
• Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics 2011;8:361-73
   PubMed Web of Science ®Google Scholar
• Schneider LS. Does donepezil improve executive function in patients with CADASIL? Lancet Neurol 2008;7:287-9
   PubMed Web of Science ®Google Scholar
• Román GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010;41:1213-21
   PubMed Web of Science ®Google Scholar
• Posada IJ, Ferrero M, López-Valdés E, Goñi-Imízcoz M. Galantamine therapy in dementia associated with CADASIL. Rev Neurol 2008;47:299-300
   PubMed Web of Science ®Google Scholar
• Yao M, Hervé D, Allili N, et al. NIHSS scores in ischemic small vessel disease: a study in CADASIL. Cerebrovasc Dis 2012;34:419-23
   PubMed Web of Science ®Google Scholar
• Dichgans M, Filippi M, Bruning R, et al. Quantitative MRI in CADASIL: correlation with disability and cognitive performance. Neurology 1999;52:1361-7
   PubMed Web of Science ®Google Scholar
• Fein G, Di Sclafani V, Tanabe J, et al. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology 2000;55:1626-35
   PubMed Web of Science ®Google Scholar
• O'Sullivan M, Rich PM, Barrick TR, et al. Frequency of subclinical lacunar infarcts in ischemic leukoaraiosis and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Am J Neuroradiol 2003;24:1348-54
   PubMed Web of Science ®Google Scholar
• Carare RO, Hawkes CA, Jeffrey M, et al. Cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination-failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol 2013; doi: 10.1111/nan.12042
   PubMed Web of Science ®Google Scholar